Ozekibart (INBRX-109) is a DR5 agonist and antitumor agent with a human DR5 IC50 of 0.17 nmol/L and human DR5 Ka of 0.11 nmol/L. Ozekibart can be used for the research of unresectable/metastatic chondrosarcoma[1].
Molecular Weight:
(105.46 kDa)
Purity:
99.63
CAS Number:
[2539847-03-3]
Target:
TNF Receptor
Application Notes:
MCE Product type: Inhibitory Antibodies
* VAT and and shipping costs not included. Errors and price changes excepted
